Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells
Chia‐Chi Hsu(National Taiwan University Hospital), James Chih‐Hsin Yang(National Taiwan University Hospital), Albert Ying-Po Yang(National Taiwan University), Pei-Chen Tai(National Taiwan University), Anya Maan-Yuh Lin(National Yang Ming Chiao Tung University), Wei-Hsun Hsu(Royal Prince Alfred Hospital), Ming-Hung Huang(National Taiwan University), Shu-Heng Lin(National Taiwan University), Hsin-Hui Tsai(National Taiwan University), Jui-Yi Chen(National Taiwan University)
Cited by 12
Related Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k